Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies

ESMO Open 2026 Open access

Read full text
Authors: K. Shitara, E. Smyth, Florian Lordick, Rupesh Pophale, C. Matney, Maria Matsangou, G. Gourgioti, Mok Oh, Radhika Ranganath, S.J. Klempner
DOI: 10.1016/j.esmoop.2025.105931
Cited by: 7
References: 16

Abstract

BACKGROUND: In the phase III SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) trials, nausea and/or vomiting were the most common adverse events in patients receiving zolbetuximab plus chemotherapy. We further characterize the adverse effects of nausea/vomiting on treatment adherence and efficacy, and evaluate strategies for managing nausea/vomiting through the SPOTLIGHT and GLOW combined analysis. MATERIALS AND METHODS: Ad hoc exploratory analyses included treatment discontinuations, antiemetic use, and progression-free survival (PFS) and overall survival (OS) after censoring patients with inadequate dose exposure (3 drug classes including steroids, for zolbetuximab-associated nausea/vomiting is important for treatment adherence and maximal clinical benefits.

Fields of Study & Subjects

Nausea and vomiting management Pregnancy and Medication Impact Chemotherapy-induced organ toxicity mitigation

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Issue
2
Pages
105931–105931
Publication date
8 January 2026
Language
EN